To those who say “impossible, impractical, unrealistic,” we say:
We are developing an innovative new class of medicines called RNAi therapeutics that we believe have the potential to transform the lives of people living with rare diseases.
AT THE FOREFRONT OF CHANGE
Alnylam is leading the translation of RNA interference (RNAi) into an innovative new class of medicines for patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including four product candidates that are in late-stage development and one product approved in the U.S. (read press release) and European Union (read press release).
updated as of March 2019
*in the U.S. and European Union
RNAi: A REVOLUTION IN BIOLOGY BUILT ON Nobel Prize-Winning Research
RNA interference (RNAi) is a breakthrough in understanding how genes are regulated in cells. It also represents a completely new approach to drug discovery and development. The 2006 Nobel Prize for Physiology or Medicine, awarded to Craig Mello and Andrew Fire, recognised the importance of RNAi as a major scientific discovery.Learn more
Our pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need that fall under 4 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS) and ocular diseases.
Our product approved for patients in the European Union treats hereditary ATTR (hATTR) amyloidosis with polyneuropathy. Our therapeutic product candidates in late-stage (Phase 2 - Phase 3) development focus on hereditary ATTR (hATTR) amyloidosis, acute hepatic porphyrias (AHPs), haemophilia and rare bleeding disorders, hypercholesterolaemia and complement-mediated diseases. We have a number of early-stage programmes in development.See our pipeline
Join our Team
As we pursue our goal of becoming a commercial organization that can independently deliver medicines to patients, we are seeking individuals with diverse skills, experiences, and backgrounds to help us build a world-class team. We are based in Cambridge, USA, with offices in Zug, Switzerland, and Maidenhead, UK, but we are also hiring throughout Europe.View current job openings
Alnylam UK Ltd.
Braywick Gate, Braywick Road, Maidenhead, Berkshire SL6 1DA
Learn More About Alnylam
In-depth information about our science, our pipeline, resources for medical professionals and patients, and the latest news about Alnylam.